Search research articles
Contact Us
Filters
Showing results (331-340 of 397) with videos related to
Page
of 40
Sort By:
Hepatology Communications
|
August 8, 2019
Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drug-Induced Liver Injury
Herbert L Bonkovsky, Tyler Severson, Paola Nicoletti, et al.
Thrombosis Research
|
May 10, 2015
Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants
Camilla L Marvig, Talitha I Verhoef, Anthonius de Boer, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
August 11, 2011
Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes
Rebecca Howard, Julian B S Leathart, David J French, et al.
Hepatology (Baltimore, Md.)
|
September 19, 2012
Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury
Manal M Monshi, Lee Faulkner, Andrew Gibson, et al.
Journal of Hepatology
|
July 23, 2011
The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver
Luca Valenti, Valerio Nobili, Ahmad Al-Serri, et al.
JHEP Reports : Innovation in Hepatology
|
April 18, 2022
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
Aidan J McGlinchey, Olivier Govaere, Dawei Geng, et al.
Hepatology (Baltimore, Md.)
|
April 8, 2010
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease
Luca Valenti, Ahmad Al-Serri, Ann K Daly, et al.
Iscience
|
September 6, 2022
Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease
Partho Sen, Olivier Govaere, Tim Sinioja, et al.
Hepatology (Baltimore, Md.)
|
April 10, 2020
Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury
Yi-Ju Li, Elizabeth J Phillips, Andrew Dellinger, et al.
Pharmacogenetics and Genomics
|
March 10, 2016
HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury
Paola Nicoletti, Anneke N Werk, Ashley Sawle, et al.
Page
of 40
Search research articles
Search
Showing results (331-340 of 397) with videos related to
Sort By:
Page
of 40
Hepatology Communications
|
August 8, 2019
Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drug-Induced Liver Injury
Herbert L Bonkovsky, Tyler Severson, Paola Nicoletti, et al.
Thrombosis Research
|
May 10, 2015
Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants
Camilla L Marvig, Talitha I Verhoef, Anthonius de Boer, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
August 11, 2011
Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes
Rebecca Howard, Julian B S Leathart, David J French, et al.
Hepatology (Baltimore, Md.)
|
September 19, 2012
Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury
Manal M Monshi, Lee Faulkner, Andrew Gibson, et al.
Journal of Hepatology
|
July 23, 2011
The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver
Luca Valenti, Valerio Nobili, Ahmad Al-Serri, et al.
JHEP Reports : Innovation in Hepatology
|
April 18, 2022
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease
Aidan J McGlinchey, Olivier Govaere, Dawei Geng, et al.
Hepatology (Baltimore, Md.)
|
April 8, 2010
Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease
Luca Valenti, Ahmad Al-Serri, Ann K Daly, et al.
Iscience
|
September 6, 2022
Quantitative modeling of human liver reveals dysregulation of glycosphingolipid pathways in nonalcoholic fatty liver disease
Partho Sen, Olivier Govaere, Tim Sinioja, et al.
Hepatology (Baltimore, Md.)
|
April 10, 2020
Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury
Yi-Ju Li, Elizabeth J Phillips, Andrew Dellinger, et al.
Pharmacogenetics and Genomics
|
March 10, 2016
HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury
Paola Nicoletti, Anneke N Werk, Ashley Sawle, et al.
Page
of 40